 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF said it has received a positive written response from the US Food and Drug Administration FDA to its pre-investigational new drug pre-IND application for the treatment of major depressive disorder MDD with BETR-001. The company said BETR-001 2-bromo-LSD, formerly TD-0148A is a non-hallucinogenic derivative of lysergic acid diethylamide LSD and is currently undergoing IND-enabling non-clinical studies and GMP manufacturing for clinical trials. 